Boston Scientific Corp. is no stranger to patent infringement litigation over stent technology. In 2010 it agreed to pay $1.7 billion to competitor Johnson & Johnson to resolve an infringement row over cardiac stents, and prior to that, it paid $50 million in 2009 to settle with a doctor who had won an infringement verdict related to a drug-releasing stent patent.
The medical device maker is embroiled in yet another stent dispute that moved closer to conclusion this week, following 10 years of litigation. On Wednesday, lawyers at Kasowitz, Benson, Torres & Friedman convinced a federal jury in Riverside, California, that Boston Scientific’s Express stent infringed a patent held by Dr. G. David Jang, and that the company breached a 2002 agreement with Jang.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
